Dexamethasone Phosphate

Suppliers

Names

[ CAS No. ]:
312-93-6

[ Name ]:
Dexamethasone Phosphate

[Synonym ]:
Hexadrol phosphate
dexamethasone-21-phosphate
Dexamethasone 21-orthophosphate
Betnelan phosphate
Dexamethasone-21-dihydrogen-phosphate
Wymesone
Neodecadron
Oradexon phosphate
Dexamethasone phosphate
[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate

Chemical & Physical Properties

[ Density]:
1.45g/cm3

[ Boiling Point ]:
669.6ºC at 760mmHg

[ Melting Point ]:
154-157°C (lit.)

[ Molecular Formula ]:
C22H30FO8P

[ Molecular Weight ]:
472.44100

[ Flash Point ]:
358.7ºC

[ Exact Mass ]:
472.16600

[ PSA ]:
151.17000

[ LogP ]:
2.01270

[ Index of Refraction ]:
1.594

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TU4055000
CHEMICAL NAME :
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-, 21-(dihydrogen phosphate)
CAS REGISTRY NUMBER :
312-93-6
LAST UPDATED :
199706
DATA ITEMS CITED :
14
MOLECULAR FORMULA :
C22-H30-F-O8-P
MOLECULAR WEIGHT :
472.49
WISWESSER LINE NOTATION :
L E5 B666 OV AHTTT&J A1 BF CQ E1 FV1OPQQO FQ G1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
36 mg/kg/90D-I
TOXIC EFFECTS :
Endocrine - changes in thymus weight Immunological Including Allergic - decrease in cellular immune response Immunological Including Allergic - decrease in humoral immune response
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 ug/kg
SEX/DURATION :
female 21-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - endocrine system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 ug/kg
SEX/DURATION :
female 19-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 ug/kg
SEX/DURATION :
female 19-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - hepatobiliary system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
30 mg/kg
SEX/DURATION :
female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
600 ug/kg
SEX/DURATION :
female 17-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
600 ug/kg
SEX/DURATION :
female 17-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 mg/kg
SEX/DURATION :
female 14-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 mg/kg
SEX/DURATION :
female 22-25 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
3 mg/kg
REFERENCE :
JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 62,527,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3850 No. of Facilities: 130 (estimated) No. of Industries: 3 No. of Occupations: 10 No. of Employees: 5388 (estimated) No. of Female Employees: 2968 (estimated)

Safety Information

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
62

[ HS Code ]:
2937290090

Synthetic Route

Precursor & DownStream

Precursor

  • Dexamethasone

DownStream

Customs

[ HS Code ]: 2937290090


Related Compounds

  • Dexamethasone phosphate
  • Dexamethasone phosphate disodium
  • Dexamethasone Sodium Phosphate
  • Dexamethasone Sodium Phosphate EP Impurity H
  • [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-17-(cyclopropanecarbonyloxy)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] cyclohexanecarboxylate
  • Dexamethasone-17,20 21-Aldehyde
  • 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole
  • Piperidine, 1-(1-oxo-2,4,12-octadecatrienyl)-, (E,E,Z)-
  • 3-(Butan-2-YL)-4-ethyl-1-methyl-1H-pyrazol-5-amine
  • N-[5-[(5-fluoro-2-methylphenyl)methoxy]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  • N-[2-({5-[(3,5-difluorobenzyl)oxy]-1H-indazol-3-yl}carbamoyl)-5-{[3-(dimethylamino)propyl](methyl)amino}phenyl]-1H-pyrrole-2-carboxamide
  • 2-amino-4-[3-(dimethylamino)propyl-methylamino]-N-(5-phenylmethoxy-1H-indazol-3-yl)benzamide
  • N-[5-[(2-methoxyphenyl)methoxy]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  • N-[5-[(4-fluorophenyl)methoxy]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  • 3-[1-({[(2-methoxyphenyl)carbamoyl]methyl}sulfanyl)-5-oxo-4H,5H-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]-N-(propan-2-yl)propanamide
  • 2-((5-(4-bromophenyl)-1-(4-fluorophenyl)-1H-imidazol-2-yl)thio)-N-methylacetamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.